Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 700 shares of the business’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $142.64, for a total transaction of $99,848.00. Following the sale, the vice president now directly owns 27,772 shares in the company, valued at approximately $3,961,398.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of NYSE EW traded down $3.97 during trading on Friday, hitting $153.18. 1,940,444 shares of the company traded hands, compared to its average volume of 2,081,948. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. Edwards Lifesciences Corp has a fifty-two week low of $103.20 and a fifty-two week high of $175.00. The firm has a market capitalization of $33.00 billion, a P/E ratio of 40.31, a P/E/G ratio of 2.08 and a beta of 0.87.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The company had revenue of $906.60 million for the quarter, compared to analyst estimates of $927.56 million. During the same quarter in the prior year, the business posted $0.84 EPS. The firm’s revenue was up 10.4% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Corp will post 4.7 EPS for the current year.
Several analysts recently weighed in on EW shares. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Wednesday, September 26th. ValuEngine raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. SunTrust Banks reduced their price objective on shares of Edwards Lifesciences to $170.00 and set a “buy” rating on the stock in a research note on Friday, August 10th. Guggenheim reaffirmed a “buy” rating and set a $170.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $168.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $156.79.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Read More: Preferred Stock
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.